Vitae Biomedical Co., Ltd. has been selected for two national-level medical device programs, reinforcing its commitment to advancing quality management systems and accelerating international market entry.

As precision medicine continues to evolve globally, the company is strengthening both its technological capabilities and regulatory readiness. From its non-invasive, high-precision lung cancer detection technology to the implementation of internationally aligned quality and manufacturing processes, Vitae Biomedical is positioning itself for global expansion.

The company has been accepted into the “Advanced and Niche Medical Device Development Program” initiated by Taiwan’s Ministry of Economic Affairs. This program provides comprehensive support, including regulatory guidance, product development resources, international market authorization strategies, and integration of AI and cloud-based technologies. Through this initiative, Vitae Biomedical aims to accelerate regulatory approvals in Southeast Asian markets.

In parallel, the company’s manufacturing facility in the Southern Taiwan Science Park has been selected for the “Medical Device Quality Management System (QMS) Guidance Program” led by the Taiwan Food and Drug Administration. This program supports the establishment of a comprehensive quality framework covering facilities, equipment, personnel, and production processes, ensuring compliance with medical device regulations and safeguarding product reliability and user safety.

With the support of these two national programs, Vitae Biomedical is advancing quality systems and regulatory pathways in parallel. This dual-track progression not only strengthens its leadership in non-invasive diagnostics but also accelerates its readiness for international commercialization and long-term growth.